Biogen Inc.
BIIB
$210.73
-$1.77-0.83%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.74B | 2.48B | 2.28B | 2.53B | 2.65B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.74B | 2.48B | 2.28B | 2.53B | 2.65B |
| Cost of Revenue | 611.60M | 610.20M | 443.40M | 508.60M | 552.50M |
| Gross Profit | 2.12B | 1.87B | 1.84B | 2.03B | 2.09B |
| SG&A Expenses | 709.70M | 607.30M | 685.20M | 592.80M | 583.80M |
| Depreciation & Amortization | 168.20M | 136.50M | 132.20M | 135.70M | 127.40M |
| Other Operating Expenses | 68.80M | 74.20M | 69.90M | 87.20M | 75.00M |
| Total Operating Expenses | 2.05B | 1.91B | 1.81B | 1.76B | 1.74B |
| Operating Income | 685.60M | 567.40M | 471.60M | 778.60M | 907.80M |
| Income Before Tax | 132.40M | 377.70M | -56.00M | 557.30M | 744.00M |
| Income Tax Expenses | 34.90M | 58.20M | -7.10M | 90.80M | 109.20M |
| Earnings from Continuing Operations | 97.50M | 319.50M | -48.90M | 466.50M | 634.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 97.50M | 319.50M | -48.90M | 466.50M | 634.80M |
| EBIT | 685.60M | 567.40M | 471.60M | 778.60M | 907.80M |
| EBITDA | 921.70M | 771.80M | 671.80M | 980.80M | 1.10B |
| EPS Basic | 0.66 | 2.17 | -0.33 | 3.18 | 4.33 |
| Normalized Basic EPS | 2.65 | 2.25 | 1.90 | 3.19 | 3.66 |
| EPS Diluted | 0.66 | 2.15 | -0.33 | 3.17 | 4.33 |
| Normalized Diluted EPS | 2.63 | 2.23 | 1.90 | 3.18 | 3.66 |
| Average Basic Shares Outstanding | 147.70M | 147.20M | 146.70M | 146.60M | 146.50M |
| Average Diluted Shares Outstanding | 148.70M | 148.40M | 146.70M | 147.10M | 146.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |